Pharmaceutical Bulk Telmisartan Powder

Pharmaceutical Bulk Telmisartan Powder

CAS:144701-48-4

MF: C33H30N4O2

MW:514.62

EINECS:620-494-7

Specification​: 99% min Telmisartan Powder

Sample: Telmisartan Powder

Packaging:1kg/bag, 25kg/drum

Brand: Henrikang

Appearance: White Powder

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Telmisartan Powder Usage and Synthesis.

Timosartan is rapidly absorbed orally and food does not interfere with absorption. The mean absolute bioavailability is about 50%. Mostly bound to plasma proteins (>99.5%).

The mean steady-state apparent volume of distribution (Vss) is about 500L, with high target organ tissue affinity. Telmisartan is not metabolised by cytochrome P450 enzymes and is metabolised by binding of the parent compound to glucosinolates. The binding product has no pharmacological activity.

The final clearance half-life is 24 hours, so only one oral dose per day is required. It peaks at 0.5-1 hour and has a rapid onset of oral antihypertensive effect. No clinically relevant accumulation of telmisartan has been observed.

When taken orally, telmisartan is almost completely excreted in the faeces, exclusively as an unchanged compound.

Uses and functions of Telmisartan.

Timosartan Tablets: for the treatment of hypertension.

Timosartan Capsules: for essential hypertension.

Timosartan Dispersible Tablets:

Used for hypertension, for the treatment of essential hypertension in adults, to reduce cardiovascular risk, age 55 years and older, in patients with a high risk of serious cardiovascular events who cannot be treated with angiotensin-converting (ACE) inhibitors to reduce the risk of myocardial infarction, stroke, or death due to cardiovascular disease.

High risk of cardiovascular events includes coronary artery disease, peripheral arterial disease, ischaemic attack or a history of high-risk type 2 diabetes mellitus or non-insulin-dependent disease with evidence of end-organ damage. Telmisartan may also be used concomitantly with other necessary therapy (e.g., antihypertensive agents, antiplatelet agents, or lipid-lowering agents); concomitant use of telmisartan with ACE inhibitors is not recommended.

Pharmacological Effects of Telmisartan Raw.

Telmisartan is a specific angiotensin II receptor (AT I type) antagonist. Telmisartan replaces the angiotensin II receptor with high affinity binding to the ATⅠ receptor subtype (a known angiotensin II site of action).

Telmisartan does not have any site agonist effect at the AT I receptor site, and telmisartan selectively binds to the AT I receptor, a binding effect that is long-lasting. Telmisartan has no affinity for other receptors, including AT2 and other less well characterised AT receptors.

The function of the other receptors mentioned above is not known, nor are the possible receptor overstimulation effects due to the increased angiotensin II levels caused by temesartan.

Telmisartan does not inhibit plasma renin or block ion channels in humans. Telmisartan does not inhibit angiotensin-converting enzyme II, which may also degrade bradykinin resulting in adverse effects due to increased bradykinin action.

In humans, 80 mg of telmisartan almost completely inhibits angiotensin II-induced increases in blood pressure. The inhibitory effect lasts for 24 hours and is still measurable at 48 hours.

The antihypertensive effect becomes progressively more pronounced within 3 hours after the first dose of telmisartan. Maximum antihypertensive effect is obtained 4 weeks after the start of treatment and can be maintained during long-term therapy.

Timosartan treatment, if abruptly interrupted, gradually returns blood pressure to pre-treatment levels after several days without rebound hypertension.

In clinical trial studies directly comparing the two hypertension medications, the incidence of dry cough was significantly lower in patients in the telmisartan-treated group than in the angiotensin-converting enzyme inhibitor-treated group.

Usage and dosage of Bulk Telmisartan Powder.

Adults:40mg - 80mg once a day. Duration of administration is not affected by diet. Patients with mild or moderate renal insufficiency, as well as the elderly take this product without dose adjustment. In patients with mild or moderate hepatic insufficiency, the dosage should not exceed 40mg/day. For children:Safety and efficacy data for this product have not been established.